INHIBRX BIOSCIENCES INC · Data as of 2026-09-08
Q4 2026
We plan to meet with the FDA in the fourth quarter of 2026 to discuss our plans to initiate a first-line registrational trial in CRC, as well as the potential for an accelerated regulatory pathway for ozekibart in fourth-line CRC.Source filing
Q1 2027
We expect to announce interim results from these cohorts during the first quarter of 2027.Source filing
Apr 14
In June 2026, the U.S. Food and Drug Administration (FDA) accepted for filing the Company's biologics license application (BLA) for the potential approval of ozekibart in conventional chondrosarcoma and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027.Source filing
Oct 23–Oct 27
We plan to announce PFS data from this trial in the fourth quarter of 2026 at the European Society for Medical Oncology 2026 Congress.Source filing